Osteoporosis and cardiovascular disease: An update

Gynecological Endocrinology

Volumn 31, Issue 8, 2015, Pages 590-594

  Lello, S ^a   Capozzi, A ^a   Scambia, G ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Cardiovascular disease; menopause; osteopenia; osteoporosis

Indexed keywords

ALENDRONIC ACID; DENOSUMAB; ESTROGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBANDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; VITAMIN D; ZOLEDRONIC ACID; BONE MORPHOGENETIC PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE;

ARTERIAL STIFFNESS; ARTICLE; BLOOD VESSEL CALCIFICATION; BONE; CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; ESTROGEN DEFICIENCY; HUMAN; OSTEOPOROSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK FACTOR; VITAMIN BLOOD LEVEL; COMPLICATION; METABOLISM;

BONE MORPHOGENETIC PROTEINS; CARDIOVASCULAR DISEASES; HUMANS; OSTEOPOROSIS; PARATHYROID HORMONE; RANK LIGAND; RISK FACTORS;

EID: 84942799952     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2015.1041908     Document Type: Article

References (70)

1. Lampropoulos CE, Papaioannou I, D'Cruz DP. Osteoporosis: a risk factor for cardiovascular disease? Nat Rev Rheumatol 2012; 8: 587-98
2. Baldini V, Mastropasqua M, Francucci CM, D'Erasmo E. Cardiovascular disease and osteoporosis. J Endocrinol Invest 2005; 28: 69-72
3. McFarlane SI, Muniyappa R, Shin JJ, et al. Osteoporosis and cardiovascular disease: brittle bones and boned arteries, is there a link? Endocrine 2004; 23: 1-10
4. Tanko LB, Christiansen C, Cummings SR, et al. Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res 2005; 20: 1912-20
5. Wu M, Rementer C, Giachelli CM. Vascular calcification: an update on mechanisms and challenges in treatment. Calcif Tissue Int 2013; 93: 365-73
6. Kawahara T, Nishikawa M, Kawahara C, et al. Atorvastatin, etidronate, or both in patients at high risk for atherosclerotic aortic plaques: a randomized, controlled trial. Circulation 2013; 127: 2327-35
7. Winkelmann BR. American Heart Association scientific sessions. Expert Opin Investig Drugs 2004; 13: 435-45
8. Tankò LB, Bagger YZ, Christiansen C. Low bone mineral density in the hip as a marker of advanced atherosclerosis in elderly women. Calcif Tissue Int 2003; 73: 15-20
9. Buckens CF, de Jong PA, Verkooijen HM, et al. Vertebral fractures on routine chest computed tomography: relation with arterial calcifications and future cardiovascular events. Int J Cardiovasc Imaging 2015; 31: 437 - 45
10. El Maghraoui A, Rezqi A, Mounach A, et al. Vertebral fractures and abdominal aortic calcification in postmenopausal women. A cohort study. Bone 2013; 56: 213-19
11. Prasad M, Reriani M, Khosla S, et al. Coronary microvascular endothelial dysfunction is an independent predictor of development of osteoporosis in postmenopausal women. Vasc Health Risk Manag 2014; 10: 533-8
12. Ness J, Aronow WS. Comparison of prevalence of atherosclerotic vascular disease in postmenopausal women with osteoporosis or osteopenia versus without osteoporosis or osteopenia. Am J Cardiol 2006; 97: 1427-8
13. Hirose K, Tomiyama H, Okazaki R, et al. Increased pulse wave velocity associated with reduced calcaneal quantitative osteo-sono index: possible relationship between atherosclerosis and osteopenia. J Clin Endocrinol Metab 2003; 88: 2573-8
14. Sumino H, Ichikawa S, Kasama S, et al. Elevated arterial stiffness in postmenopausal women with osteoporosis. Maturitas 2006; 55: 212-18
15. Frost ML, Grella R, Millasseau SC, et al. Relationship of calcification of atherosclerotic plaque and arterial stiffness to bone mineral density and osteoprotegerin in postmenopausal women referred for osteoporosis screening. Calcif Tissue Int 2008; 83: 112-20
16. Cecelja M, Jiang B, Bevan L, et al. Arterial stiffening relates to arterial calcification but not to noncalcified atheroma in women. A twin study. J Am Coll Cardiol 2011; 57: 1480-6
17. Aksoy Y, Yagmur C, Tekin GO, et al. Aortic valve calcification: association with bone mineral density and cardiovascular risk factors. Coron Artery Dis 2005; 16: 379-83
18. McCarty MF, Di Nicolantonio JJ. The molecular biology and pathophysiology of vascular calcification. Postgrad Med 2014; 126: 54-64
19. Fernández-Murga ML, Vinué Á, Caeiro JR, et al. Impact of estrogens on atherosclerosis and bone in the apolipoprotein E-deficient mouse model. Menopause 2015; 22: 428 - 36
20. Igase M, Kohara K, Tabara Y, et al. Change in arterial stiffness associated with monthly bisphosphonate treatment in women with postmenopausal osteoporosis. Menopause 2014; 21: 962-6
21. Jakob F, Seefried L, Schwab M. Age and osteoporosis. Effects of aging on osteoporosis, the diagnostics and therapy. Internist (Berl). 2014; 55: 755-61
22. Seeman E, Delmas PD. Bone quality-the material and structural basis of bone strength and fragility. N Engl J Med 2006; 354: 2250-61
23. Hauge EM, Qvesel D, Eriksen EF, et al. Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers. J Bone Miner Res 2001; 16: 1575-82
24. Villella E, Cho JS. Effect of aging on the vascular system plus monitoring and support. Surg Clin North Am 2015; 95: 37-51
25. Prasad DS, Das BC. Physical inactivity: a cardiovascular risk factor. Indian J Med Sci 2009; 63: 33-42
26. Carter MI, Hinton PS. Physical activity and bone health. Mo Med 2014; 111: 59-64
27. Abrahamsen B, Brask-Lindemann D, Rubin KH, et al. A review of lifestyle, smoking and other modifiable risk factors for osteoporotic fractures. Bonekey Rep 2014; 3: 574
28. Okazaki R. Fracture risk associated with drugs other than glucocorticoids. Clin Calcium 2014; 24: 357-65
29. Szabó A. Skeletal and extra-skeletal consequences of vitamin D deficiency. Orv Hetil 2011; 152: 1312-19
30. Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992; 327: 1637-42
31. Adami S, Giannini S, Bianchi G, et al. Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporos Int 2009; 20: 239-44
32. Querales MI, Cruces ME, Rojas S, et al. Association between vitamin D deficiency and metabolic syndrome. Rev Med Chil 2010; 138: 1312-18
33. Takx RA, Zanen P, Leiner T, et al. The interdependence between cardiovascular calcifications in different arterial beds and vascular risk factors in patients at high cardiovascular risk. Atherosclerosis 2014; 238: 140-6
34. O'Leary SA, Mulvihill JJ, Barrett HE, et al. Determining the influence of calcification on the failure properties of abdominal aortic aneurysm (AAA) tissue. J Mech Behav Biomed Mater 2014; 42C: 154-67
35. Osako MK, Nakagami H, Koibuchi N, et al. Estrogen inhibits vascular calcification via vascular RANKL system: common mechanism of osteoporosis and vascular calcification. Circ Res 2010; 107: 466-75
36. Sprini D, Rini GB, Di Stefano L, et al. Correlation between osteoporosis and cardiovascular disease. Clin Cases Miner Bone Metab 2014; 11: 117-19
37. Hamerman D. Osteoporosis and atherosclerosis: biological linkages and the emergence of dual-purpose therapies. QJM 2005; 98: 467-84
38. Kostenuik PJ. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol 2005; 5: 618-25
39. Lee CJ, Wang JH, Chen ML, et al. Serum osteoprotegerin is associated with arterial stiffness assessed according to the cardio-ankle vascular index in hypertensive patients. J Atheroscler Thromb 2015; 22: 304 - 12
40. Lindberg S, Jensen JS, Hoffmann S, et al. Osteoprotegerin levels change during STEMI and reflect cardiac function. Can J Cardiol 2014; 30: 1523-8
41. Wolak T. Osteopontin-a multi-modal marker and mediator in atherosclerotic vascular disease. Atherosclerosis 2014; 236: 327-37
42. Evrard S, Delanaye P, Kamel S, et al. Vascular calcification: from pathophysiology to biomarkers. Clin Chim Acta 2014; 438C: 401-14
43. Mazzaferro S, Tartaglione L, Rotondi S, et al. News on biomarkers in CKD-MBD. Semin Nephrol 2014; 34: 598-611
44. Tella SH, Gallagher JC. Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol 2014; 142: 155-70
45. Blair HC, Zaidi M. Osteoclastic differentiation and function regulated by old and new pathways. Rev Endocr Metab Disord 2006; 7: 23-32
46. Lee NK, Choi YG, Baik JY, et al. A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation. Blood 2005; 106: 852-9
47. McLean RR. Proinflammatory cytokines and osteoporosis. Curr Osteoporos Rep 2009; 7: 134-9
48. Dischereit G, Lange U. Osteoporosis-inflammatory effects on bone metabolism and fracture risk. Z Orthop Unfall 2014; 152: 170-6
49. Cervellati C, Bonaccorsi G, Cremonini E, et al. Oxidative stress and bone resorption interplay as a possible trigger for postmenopausal osteoporosis. Biomed Res Int 2014; 2014: 569563
50. Agarwal A, Aponte-Mellado A, Premkumar BJ, et al. The role of oxidative stress of female reproduction: a review. Reprod Biol Endrocrinol 2012; 10: 1-32
51. Michalak A, Krzeszowiak J, Markiewicz-Górka I. The correlations between aging of the human body, oxidative stress and reduced efficiency of repair systems. Postepy Hig Med Dosw (Online) 2014; 68: 1483-91
52. Cagnacci A, Cannoletta M, Palma F, et al. Relation between oxidative stress and climacteric symptoms in early postmenopausal women. Climacteric 2015: 1-6
53. Demir B, Demir E, Aciksari G, et al. The association between the epicardial adipose tissue thickness and oxidative stress parameters in isolated metabolic syndrome patients: a multimarker approach. Int J Endocrinol 2014; 2014: 954045
54. Zhang H, Tao X, Wu J. Association of homocysteine, vitamin B12, and folate with bone mineral density in postmenopausal women: a meta-analysis. Arch Gynecol Obstet 2014; 289: 1003-9
55. Saito M, Kida Y, Marumo K. Bone metabolism and cardiovascular function update. The estimation of bone material quality in the concept of bone and vascular linkage. Clin Calcium 2014; 24: 27-35
56. Saito M, Marumo K. Bone quality in lifestyle-related diseases. Clin Calcium 2011; 21: 655-60
57. Fehérvári M, Sarkadi H, Krepuska M, et al. Bone mineral density is associated with site-specific atherosclerosis in patients with severe peripheral artery disease. Calcif Tissue Int 2013; 93: 55-61
58. Papapoulos SE. Bisphosphonates: how do they work? Best Pract Res Clin Endocrinol Metab 2008; 22: 831-47
59. Igase M, Kohara K, Tabara Y, et al. Change in arterial stiffness associated with monthly bisphosphonate treatment in women with postmenopausal osteoporosis. Menopause 2014; 21: 962-6
60. Gonnelli S, Caffarelli C, Tanzilli L, et al. Effects of intravenous zoledronate and ibandronate on carotid intima-media thickness, lipids and FGF-23 in postmenopausal osteoporotic women. Bone 2014; 61: 27-32
61. Celiloglu M, Aydin Y, Balci P, Kolamaz T. The effect of alendronate sodium on carotid artery intima-media thickness and lipid profile in women with postmenopausal osteoporosis. Menopause 2009; 16: 689-93
62. Vestergaard P. Acute myocardial infarction and atherosclerosis of the coronary arteries in patients treated with drugs against osteoporosis: calcium in the vessels and not the bones? Calcif Tissue Int 2012; 90: 22-9
63. Okamoto M, Yamanaka S, Yoshimoto W, et al. Alendronate as an effective treatment for bone loss and vascular calcification in kidney transplant recipients. J Transplant 2014; 2014: 269613
64. Santos LL, Cavalcanti TB, Bandeira FA. Vascular effects of bisphosphonates-a systematic review. Clin Med Insights Endocrinol Diabetes 2012; 5: 47-54
65. Elmariah S, Delaney JA, O'Brien KD, et al. Bisphosphonate use and prevalence of valvular and vascular calcification in women MESA (The Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 2010; 56: 1752-9
66. Panizo S, Cardus A, Encinas M, Parisi E, et al. RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway. Circ Res 2009; 104: 1041-8
67. Deuell KA, Callegari A, Giachelli CM, et al. RANKL enhances macrophage paracrine pro-calcific activity in high phosphate-treated smooth muscle cells: dependence on IL-6 and TNF-α. J Vasc Res 2012; 49: 510-21
68. Capozzi A, Lello S, Pontecorvi A. The inhibition of RANK-ligand in the management of osteoporosis and related fractures: the role of Denosumab. Gynecol Endocrinol 2014; 30: 403 - 8
69. Helas S, Goettsch C, Schoppet M, et al. Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice. Am J Pathol 2009; 175: 473-8
70. Samelson EJ, Miller PD, Christiansen C, et al. RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk. J Bone Miner Res 2014; 29: 450-7